Articles tagged with Cancer Cells
Researchers demonstrate that the innate immune system recognizes weaker cells and activates programmed cell death, eliminating them in a process called cell competition. This phenomenon has implications for cancer research and early disease detection.
Researchers at the University of Adelaide have discovered that cancer cells with chromosomal instability are vulnerable to mild metabolic disruption, making them a potential target for new therapy. The study's findings suggest that targeting these unstable cells could lead to more effective treatments with fewer side effects.
Researchers found high-dose interleukin-2 to be effective in metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, achieving durable complete responses in a selected population. The therapy's efficacy and safety were confirmed, offering an alternative treatment option for carefully selected patients.
Researchers at MIT have developed a load driver device that can reduce unpredictability in biological circuits, allowing for robust and predictable behavior. This breakthrough could lead to applications such as biosensing and glucose monitoring for diabetic patients.
Researchers mapped p53 binding sites in human cancer and normal cells, finding the protein binds selectively to repeat sequences in cancer cells. This suggests p53's role in maintaining genomic stability and tumor suppression is context-dependent.
Researchers established induced pluripotent stem (iPS) cells from Werner syndrome fibroblasts, which can be used for drug discovery and gene therapy. The iPS cells have recovered telomeric abnormalities and similar expression levels of aging-related genes as normal iPS cells.
Research reveals Chlamydia trachomatis breaks down protective protein p53, allowing cells to mutate and develop into cancer. The bacterium exploits this mechanism to survive within host cells, posing a potential risk for cancer development.
Researchers have solved a decades-old mystery by uncovering the formation of massive DNA molecules, dubbed 'neochromosomes', in some tumours. These giant chromosomes are formed through catastrophic chromosomal shattering and genetic amplification, ensuring the cancer's survival.
Researchers have determined the structure of an ABC transporter complex, enabling targeted therapeutic approaches to combat antibiotic resistance and cancer cell defense. The study's breakthrough has significant implications for treating cystic fibrosis, bacterial infections, and cancer.
Researchers found a new strategy and potential drug to target faulty Ras protein, which causes cancer by producing excess signals. This breakthrough offers opportunities for developing new treatments that exploit the discovery without harming healthy cells.
Researchers have successfully triggered the self-destruct process in lung cancer cells, paving the way for a new treatment approach that leaves healthy cells unharmed. The breakthrough was achieved using a combination of two drugs, TRAIL and a CDK9 inhibitor, which altered the molecular switches in the cell suicide process.
Melbourne researchers have discovered the three-dimensional structure of a key cell death protein called Bak and revealed how it causes cell death. The study offers new targets for treating diseases such as lupus, cancers, and neurodegenerative disorders.
Two new studies from Johns Hopkins shed light on how complex cells detect and respond to minute differences in chemical concentrations. Cells use their internal 'skeleton' to influence gradient detection and movement, with implications for development, immune response, wound healing, and cancer metastasis.
Bio-engineers at ETH Zurich have created a biological circuit that controls sensor components using internal timers, enabling precise signal transmission. This breakthrough could lead to reprogramming cancer cells and creating complex bio-computers to detect and kill cancer cells.
The study identifies tiny differences in protein sequences between cancer cells and healthy tissue, enabling the creation of personalized vaccines. The research aims to improve treatment outcomes for patients with ovarian cancer, which often responds well to surgery and chemotherapy but returns lethally within a year or two.
A team of scientists has uncovered a new mechanism controlling actin-rich protrusions that aid in cell migration, a process essential for development, wound healing, and immunological responses. GMF protein plays a key role in regulating these protrusions.
Researchers at Imperial College London have developed a new cancer drug, DTP3, that selectively kills multiple myeloma cells without causing toxicity. The drug works by stopping the NF-kB pathway, which allows cancer cells to multiply, and has been awarded funding for clinical trials in patients with multiple myeloma.
Researchers at North Carolina State University have developed a DNA-based drug delivery system that targets cancer cells using nano-cocoons made of DNA. The system uses self-assembling DNA techniques and specifically delivers anticancer drugs to cancer cells, releasing them quickly once inside.
Researchers discovered that chromosome rearrangements can induce additional errors in cell division, leading to genetic instability. The study found that misplaced DNA segments can lead to the formation of extra cohesion sites, causing abnormal chromosome stretching during cell division.
Researchers found that nuclear factor kappa B (NF-kB) enables cancer cells to evade the immune system by suppressing genes that inhibit the immune response. Inhibiting NF-kB may make tumor cells more vulnerable to elimination by the immune system.
Researchers created a computer model that captures the exosomal exchange between cancer cells, dendritic cells, and other immune system cells. This new approach aims to find a better balance between cancer and the immune system, potentially leading to reduced side effects and improved treatment outcomes.
A $470,350 NSF award will support research on how proteins form groups or clusters within cells, which is associated with cancer and heart arrhythmias. The project aims to gain a better understanding of normal and abnormal protein grouping to prevent or correct abnormalities.
Researchers created a novel method for cell migration by mimicking the connective tissue environment, allowing cells to move in a controlled direction. This breakthrough could lead to new approaches in combating cancer metastasis and inflammation.
A new study reveals that individual cells' migration speed changes randomly through successive generations, despite the population's average speed remaining constant. This finding has significant implications for cancer treatment and tissue repair, suggesting a target for drugs to modulate cell migration speed.
Researchers have found that protein AIM can prevent liver cancer development by triggering the complement cascade to eliminate cancerous cells. AIM accumulates on the surface of HCC cells, leading to their destruction.
Researchers at the University of Missouri have discovered a molecule that effectively treats oxidative stress, which is linked to cancer, Alzheimer's, and Parkinson's disease. The compound, HPP-4382, has shown promise in fighting free radicals and could eventually be developed into a drug.
Phase II data showed dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer. HER2 inhibition also shows promise in HER2-positive non-small cell lung cancer, with a 21% overall response rate in patients treated with neratinib and temsirolimus.
Researchers at the University of Missouri have discovered that a molecule used by bacteria can prevent cancer cells from spreading and even kill them. The 'stop spreading' bacteria molecule was found to stop multiplying, migrate, and begin dying in human pancreatic cancer cells.
Researchers have identified a better measure of predicting cancer neoepitopes, which are specific protein sequences recognized by immune cells. This new approach has the potential to improve current methods for generating anticancer vaccines, increasing their effectiveness in combating cancer.
A new technique uses perfluorocarbon tracers in combination with MRI to track therapeutic immune cells injected into patients with colorectal cancer. The study found that only half of the delivered cell vaccine remained at the inoculation site after 24 hours, but the technology shows promise for tracking other cell types and diseases.
Researchers at the Salk Institute have discovered a 'switch' in cells that can be turned on and off to control telomerase activity. This switch could help keep telomerase levels low, potentially slowing aging and regenerating vital organs.
The NIH has awarded over $64 million to six institutions to create a database of human cellular responses, known as the Library of Integrated Network-based Cellular Signatures (LINCS). This will improve scientists' understanding of cell pathways and aid in the development of new therapies for many diseases.
Ovarian cancer cells use mesothelial cells to spread through the body via fibronectin secretion. The study suggests that mesothelium is an active participant in the spread of ovarian cancer.
Researchers at Thomas Jefferson University have discovered a novel approach to killing colon cancer cells by using an antibody that targets the GUCY2C receptor, which is over-produced and exhibited on the surface of cancer cells. The immunotoxin selectively destroys colon cancer cells while sparing surrounding tissue.
A new cancer drug targeting mitochondrial function has been proven safe and showed some efficacy in a Phase I clinical trial for leukemia patients. The drug selectively shut down energy production in cancer cells, which can reproduce faster and repair damage from chemotherapy.
Researchers have developed an innovative algorithm that identifies synthetic lethal interactions in cancer, enabling personalized treatment and predicting patient prognosis. The study's findings show promise for repurposing existing drugs to target specific cancer types.
Yale Cancer Center researchers have found that lupus antibodies can selectively attack and kill cancer cells with defective DNA repair mechanisms. The study, led by James E. Hansen, suggests that harnessing these antibodies could be a new approach to targeted cancer therapy.
A new study confirms the role of invadopodia in cancer spread, showing that preventing their formation can stop cancer entirely. The study identifies a potential therapeutic target for drug development to prevent invadopodia formation.
Researchers have created an online analytic platform called CellNet to aid stem cell engineering. The tool uses network biology methods to analyze and predict cell fate and corresponding engineering strategies, offering a reliable shortcut for drug development and individualized cancer therapies.
Cells with oncogenic H-RAS activate ROS, which inactivates PTP1B, leading to AGO2 phosphorylation and gene silencing. This results in the accumulation of p21 proteins and halting the cell cycle.
Researchers at Virginia Commonwealth University Massey Cancer Center have developed a novel cancer therapy that leverages the autophagy defense mechanism to induce cell death in multiple myeloma cells. By targeting the p62 protein, the therapy disrupts autophagy and triggers apoptosis, resulting in increased effectiveness compared to t...
Researchers at Duke University have uncovered a 'roving detection system' on cell surfaces that may lead to new cancer therapies. The system involves receptors that search for signals to guide cell movement, potentially allowing for the prevention of metastasis and other diseases.
Researchers found BIM deletion independently predicts overall and progression-free survival in advanced NSCLC patients, particularly in those treated with EGFR TKIs or chemotherapy. The study suggests considering BIM deletion as a clinical trial stratification factor for Asian NSCLC patients.
Researchers at Children's Hospital Los Angeles have developed a method to multiply natural killer cells from patients with leukemia in the lab. These autologous NK cells can be used to destroy cancer cells, potentially providing a less toxic and more effective treatment for pediatric leukemia.
The MGH device tracks the movement of cells passing through a comb-like array, allowing researchers to study epithelial-mesenchymal transition and its role in tumor metastasis. This process enables cancer cells to break off from primary tumors and invade other tissues.
Researchers have shed new light on the epithelial-mesenchymal transition (EMT) process in cancer cells, using a microengineered device that acts as an obstacle course for cells. The study reveals that EMT upgrades cancer cells from an economy model to a fast sports car, allowing them to migrate aggressively to distant locations.
The NIH Follow that Cell Challenge seeks tools to monitor a cell's behavior and function over time, potentially leading to earlier diagnosis and improved therapies for diseases. The challenge aims to generate creative ideas and methods for following a single cell's behavior, using multiple integrated measures.
Researchers at the Salk Institute have identified a key control mechanism on regulatory T cells that maintain immune system balance. Removing a specific genetic sequence in Foxp3 destabilizes these cells, leading to autoimmune disease in animal models.
Chloroquine has been shown to inhibit tumor growth and metastases by normalizing abnormal blood vessels in tumors. This results in an increased barrier function blocking cancer cell dissemination and enhanced tumor perfusion increasing the response of the tumor to chemotherapy.
Researchers have created a synthetic ion transporter that can cause cancer cells to self-destruct by disrupting the delicate balance of ions within their cell membranes. The molecule, which was discovered after two decades of research, confirms a hypothesis that could lead to new anticancer drugs and benefit patients with cystic fibrosis.
Researchers at Duke University have successfully used CRISPR gene-editing to target and destroy two HPV genes responsible for cervical cancer cell growth. By hijacking the bacterial defense system, they were able to selectively kill cancer cells while leaving normal cells intact.
Researchers have identified a specific gene required for human cells to survive chromosomal defects that occur as cells divide over time. The discovery sheds light on the mechanisms behind cancer cell survival and holds promise for developing new treatments.
Researchers at Cardiff University have identified a specific gene, Ligase 3, that human cells require to survive chromosomal defects and evade death. This discovery has significant implications for understanding the development of cancer and could lead to new therapeutic targets.
A team of international researchers, led by Professor Wayne Brodland from the University of Waterloo, found that wounds knit together through a complex process involving cellular crawling and contraction. This discovery has potential applications in addressing major health issues such as birth defects and cancer
University of Michigan researchers identified a protein called TRIP13 that enables cancer cells to repair themselves and survive despite chemotherapy. The team found an existing chemical compound that can block this process, potentially increasing the effectiveness of cancer treatment and improving patient survival rates.
Scientists at the University of Kent have discovered how cells regulate internal structures, known as actin filaments. The research could lead to new therapies for diseases like cancer.
Researchers at EPFL discovered that cancer cells with high sugar intake and mobility have a similar mechanism, promoting metastasis and influencing patient survival. The intensity of this phenomenon significantly impacts survival rates, making GLUT3 a potential target for future therapies.
Cancer cells can divide even without sufficient oxygen by manipulating the protein HIF-1alpha. Lysosomes play a crucial role in regulating this process by marking or degrading HIF-1alpha. The study suggests that inhibiting Cdk2 may be an effective treatment strategy for certain types of cancer.
Researchers found a significant reduction in cervical cancer risk after removing squamocolumnar junction (SCJ) cells, which are implicated as the origins of cervical cancer. The study showed that removal of SCJ cells altered recurrence patterns and may prevent precancerous growths.
Researchers reveal detailed images of anaphase-promoting complex (APC/C), a protein that controls mitosis. The discovery could lead to new cancer drugs by identifying binding sites for future treatments.